BlossomHill Therapeutics, Inc. (BLSM) Stock Statistics & Valuation Metrics

BlossomHill Therapeutics, Inc. has a market cap or net worth of $627.75M. The enterprise value is ―.

BlossomHill Therapeutics, Inc. has 31,784,908 shares outstanding. The number of shares has decreased by -2.65% in one year.

BlossomHill Therapeutics, Inc.’s return on equity (ROE) is 0.46 and return on invested capital (ROIC) is -43.41%.

The current PE Ratio of BlossomHill Therapeutics, Inc. is ―. BlossomHill Therapeutics, Inc.’s PEG ratio is -0.08.

In the last 12 months, BlossomHill Therapeutics, Inc. had revenue of 0.00 and earned -60.55M in profits. Earnings per share was -2.08.

In the last 12 months, operating cash flow was -44.17M and capital expenditures -13.00K, giving a free cash flow of -44.19M billion.

BlossomHill Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

BlossomHill Therapeutics, Inc. upcoming earnings date is Sep 18, 2026, Before Open (Confirmed).

BlossomHill Therapeutics, Inc. as a current ratio of 8.97, with Debt / Equity ratio of 28.49%

In the past 12 months, BlossomHill Therapeutics, Inc. has paid 0.00 in taxes.

BlossomHill Therapeutics, Inc. EV to EBITDA ratio is -5.52, with an EV/FCF ratio of -7.31.

BlossomHill Therapeutics, Inc. has $95.38M in cash and marketable securities with $23.37M in debt, giving a net cash position of $72.00M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for BlossomHill Therapeutics, Inc. is $35.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy